I just wish I would have found this company back in November when it was below $1. But it still looks like it is undervalued and a good buy at these levels.
The other thing I like is that it looks like they can get their products to the market faster than a drug, if everything goes right.
Looks like this is really under the radar. 2012 could be the year when some eyes start looking at NVIV.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.